At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
New panels target EGFR Pathways, clinically relevant myeloid genes, and TP53
Alameda, CA, December 10, 2019 - Fluxion Biosciences announced today the launch of three new Spotlight targeted NGS liquid biopsy panels: Spotlight Comprehensive TP53, Spotlight EGFR Pathway, and Spotlight Myeloid. These new panels complement Fluxion’s current pan-cancer panel, Spotlight 59. Each of the panels has been validated with Fluxion’s ERASE-Seq variant caller, and they are intended for use with cfDNA, CTCs, and FFPE.
The new panels have been launched to address needs among researchers for focused liquid biopsy panels targeting key research areas:
Spotlight EGFR Liquid Biopsy Panel The Spotlight EGFR Liquid Biopsy NGS Pathway Panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight EGFR Pathway Panel is compatible with short DNA fragments from both cfDNA and FFPE samples. This panel is especially well-suited for research focused on detecting clinically-relevant allele variants in DNA from cell-free DNA (cfDNA) and circulating tumor cells (CTCs).
Spotlight Myeloid Liquid Biopsy Panel Spotlight Myeloid is a 478-amplicon panel covering 23 clinically-relevant genes implicated in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (NPM). Because of the high prevalence of myeloid variants in clonal hematopoiesis of indeterminate potential (CHIP) studies, this is an ideal panel for uncovering CHIP variants in either cell-derived or cfDNA samples.
Spotlight TP53 Liquid Biopsy Panel Spotlight TP53 contains 21 amplicons with an average size of 140 bp that provides comprehensive coverage of all coding regions of TP53. The Spotlight TP53 Panel is compatible with short DNA fragments from cfDNA and FFPE samples.
Each of these new panels is powered by ERASE-Seq, Fluxion’s statistically powered variant caller that is available free of charge to Spotlight users. ERASE-Seq utilizes statistical analysis to compare sequencing results to a detailed background model and multiple sample amplification pools (MAPs). This approach eliminates both random errors and systemic biases inherent in all sequencing workflows. ERASE-Seq delivers superior detection sensitivity to 0.1% allele frequency and below, with a false positive rate 10-100X lower than leading molecular barcode approaches.
Fluxion’s pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, Spotlight™ Oncology Panels for ultra-sensitive mutation detection from cfDNA, and the ERASE-Seq variant caller for liquid biopsies. Fluxion’s technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion Biosciences’ liquid biopsy capabilities, visit http://liquidbiopsy.fluxionbio.com.